Company Revenue Reports

While the company's orthopedic segments continue to recover from the April low point, the Mako robotic system continued its strong growth trend in 2Q20.

The company's international viscosupplement sales declined by nearly -40% in 2Q20 as COVID continues to spread in Seikagaku's key U.S. market.

The company's orthopedic sales fell -34% in 2Q20, but Smith+Nephew is strategically positioned to benefit from the acceleration in ASC procedures.

Amplitude's sales fell nearly -14% for their fiscal year 2020 due to COVID-19, but the company's foot and ankle products still managed double-digit growth.

Second quarter revenue declines for DePuy Synthes were not as significant as expected. The company updated its 2020 guidance modeling reduced COVID impact.

The company's orthopedic revenues for its fiscal fourth quarter fell -35% as it endured an additional month of COVID-related impact in April compared to competitors.

The company grew in FY19 despite COVID-related declines in its fourth quarter, driven by both reimbursement wins and competitive account conversions.

The company was able to offset deeper COVID-related declines on the strength of its advanced DBM portfolio and plans to pursue several alpha launches of new products in 2020.

Geographic factors and a highly elective portfolio exposed the company to a severe downturn due to COVID-19, with 1Q20 revenue down 20% and April revenues down 95%.

While the company's orthopedic revenues declined in the high single-digits in 1Q20, Zimmer Biomet's balance sheet and cost containment measures will allow it to aggressively pursue key R&D initiatives.